Heidi Mizenko

Senior Human Resources Associate at Vigil Neuro

Heidi Mizenko is currently a Human Resources Associate at Vigil Neuro. Heidi has also worked as an MBA Consultant at Newton Community Pride and as a Development Graduate Assistant at Brandeis University.

As an MBA Consultant, Mizenko led a team of four MBA students in measuring the Total Economic Activity and Social Impact of Newton’s art and cultural community. This resulted in quantifying the outcomes of the $19,305,690 that the arts contributed to the Newton Community. Mizenko also assessed community stakeholders through 400 survey responses with Qualtrics XM, interviews, and financial statements. Additionally, they identified the direct and indirect impact of organization and audience expenditures. Finally, they secured $75,000 of city funding for their client through the development and presentation of an Economic Impact Report.

As a Development Graduate Assistant at Brandeis University, Mizenko strengthened donor and alumni relations by launching giving campaigns, utilizing email marketing strategies, tracking alumni engagement, and moderating 4 Heller Alumni Board meetings. Heidi also launched a Giving Tuesday Campaign and Student Giving Campaign that raised over $10,000. In addition, Mizenko awarded over 100 Heller Students scholarships of $250 or more from the Heller Annual Fund.

Heidi Mizenko has a Master of Business Administration from the Heller School for Social Policy and Management at Brandeis University. Heidi also has a BA in International Studies from North Carolina State University. Heidi has participated in an exchange program at NEOMA Business School.

Location

Boston, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Vigil Neuro

Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.


Employees

51-200

Links